One Health monitoring: zoonoses and resistance

Antibiotic resistance is usually discovered in a human clinic, at which point it has already finished most of its journey. The genes encoding it evolve largely elsewhere: in livestock under constant selective pressure, in soil and water microbes naturally producing antibiotics, in wildlife interfaces. They then travel — not necessarily inside pathogens but aboard shared mobile elements such as plasmids, which transfer freely across bacterial species. Monitoring human medicine alone therefore reads the final chapter; One Health surveillance reads animals, people and environment as one connected system, on the premise that resistance genes commute between compartments far faster than the diseases themselves.

Genes commute; species do not fence

The molecular traffic runs continuously. Antibiotic use in animal husbandry selects resistant gut floras; manure fertilises fields and reaches watercourses; food, irrigation, workers and wildlife carry organisms between compartments; and plasmid exchange lets resistance genes hop into whatever pathogens circulate downstream. A resistance gene found in a hospital ICU can share ancestry with one documented months earlier in a poultry operation — reconstruction of such journeys from genome sequences has become routine microbiological forensics. The surveillance consequence is structural rather than rhetorical: sampling only humans guarantees late detection, because the events that assemble tomorrow’s clinical resistance happen today in barns, effluent lagoons and market stalls.

What sequencing measures — and what it doesn’t

Shotgun metagenomics reads everything in a sample at once, then maps recovered sequences against curated resistance-gene databases to profile a sample’s resistome: which determinants are present, in what relative abundance, alongside any pathogens sharing the specimen. This breadth-for-certainty trade deserves clear statement. Gene detection does not equal phenotypic resistance — genes may sit silent, incomplete or absent from expressed plasmids — so definitive susceptibility still requires culturing the organism in question. Metagenomics answers a different question with speed and breadth: what resistance potential circulates in this compartment, trending which way, and arriving with which pathogen neighbours. The two readouts complement; neither replaces the other, and mature programmes run both.

Where the lead time lives

Spillover risk concentrates at interfaces: live-animal markets, farm runoff, abattoir chains, wildlife-livestock boundaries. Sampling there buys calendar room — detecting a viral lineage circulating in poultry weeks before human clusters appear, or watching a resistance-gene family’s abundance climb in runoff before it colonises a hospital. Dashboard risk-scoring translates these signals into priorities, though its arithmetic inherits an old epistemic debt: surveillance that succeeds produces nothing countable — the outbreak that never happened — so programme value must be argued from coverage, trend reversals and modelled counterfactuals rather than victories tallied. This structural invisibility, more than any laboratory limitation, is what long-term funders must accept on faith. Within the same molecular toolkit as its urban sibling — the metagenomic surveillance of cities and the environmental sampling of wastewater — One Health monitoring extends the lens to the reservoirs where tomorrow’s clinical problems are currently incubating unobserved.